Advertisement
Advertisement
BMY
Bristol-Myers Squibb Co.
58.22
USDSponsored
-2.37
-3.91%
May 01, 16:00 UTC -4
Closed
After-Market
58.40
+0.18
+0.31%
BMY Earnings Reports
Positive Surprise Ratio
BMY beat 36 of 41 last estimates.
88%
Next Report
Date of Next Report
Jul 30, 2026
Estimate for Q2 26 (Revenue/ EPS)
$11.95B
/$1.65
Implied change from Q1 26 (Revenue/ EPS)
+4.00%
/+4.43%
Implied change from Q2 25 (Revenue/ EPS)
-2.61%
/+13.01%
Bristol-Myers Squibb Co. earnings per share and revenue
On Apr 30, 2026, BMY reported earnings of 1.58 USD per share (EPS) for Q1 26, beating the estimate of 1.42 USD, resulting in a 10.95% surprise. Revenue reached 11.49 billion, compared to an expected 10.96 billion, with a 4.82% difference. The market reacted with a +5.21% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 10 analysts forecast an EPS of 1.65 USD, with revenue projected to reach 11.95 billion USD, implying an increase of 4.43% EPS, and increase of 4.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Alnylam Pharmaceuticals, Inc.
Report Date
Apr 30, 2026 For Q1 26
Estimate
$0.95
Actual
$1.99
Surprise
+108.95%
Moderna, Inc. Common Stock
Report Date
May 01, 2026 For Q1 26
Estimate
-$3.32
Actual
-$1.18
Surprise
+64.48%
Illumina Inc
Report Date
Apr 30, 2026 For Q1 26
Estimate
$1.07
Actual
$1.14
Surprise
+6.94%
Bio-Rad Laboratories, Inc. Class B
Report Date
Apr 30, 2026 For Q1 26
Estimate
$2.00
Actual
$1.89
Surprise
-5.68%
Kymera Therapeutics, Inc. Common Stock
Report Date
Apr 30, 2026 For Q1 26
Estimate
-$0.89
Actual
-$0.71
Surprise
+21.05%
Syndax Pharmaceuticals, Inc.
Report Date
Apr 30, 2026 For Q1 26
Estimate
-$0.59
Actual
-$0.48
Surprise
+19.15%
NovoCure Limited Ordinary Shares
Report Date
Apr 30, 2026 For Q1 26
Estimate
-$0.52
Actual
-$0.62
Surprise
-18.52%
Phathom Pharmaceuticals, Inc. Common Stock
Report Date
Apr 30, 2026 For Q1 26
Estimate
-$0.32
Actual
-$0.18
Surprise
+45.22%
Pacira BioSciences, Inc. Common Stock
Report Date
Apr 30, 2026 For Q1 26
Estimate
$0.57
Actual
$0.60
Surprise
+4.42%
Emergent Biosolutions, Inc.
Report Date
Apr 30, 2026 For Q1 26
Estimate
-$0.25
Actual
$0.21
Surprise
+183.17%
FAQ
What were Bristol-Myers Squibb Co.'s earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Bristol-Myers Squibb Co. reported EPS of $1.58, beating estimates by 10.95%, and revenue of $11.49B, 4.82% above expectations.
How did the market react to Bristol-Myers Squibb Co.'s Q1 2026 earnings?
The stock price moved up 5.21%, changed from $57.59 before the earnings release to $60.59 the day after.
When is Bristol-Myers Squibb Co. expected to report next?
The next earning report is scheduled for Jul 30, 2026.
What are the forecasts for Bristol-Myers Squibb Co.'s next earnings report?
Based on 10
analysts, Bristol-Myers Squibb Co. is expected to report EPS of $1.65 and revenue of $11.95B for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement